AIDS CLINICAL TRIALS GROUP - ACTU

说明(改编自申请书摘要)：自成立以来 1987年，辛辛那提大学(UC)ACTU为 委员会在若干关键领域的总体任务。加州大学ACTU有 提供科学和行政领导，特别是在 机会性感染，以及最近在抗逆转录病毒研究中，艾滋病毒- 相关神经疾病、研究护理和研究设计。在 当前周期，加州大学ACTU建议继续执行广泛的 临床试验和子研究以确保UC ACTU对 委员会研究议程的目标。其中包括将 加州大学在免疫发病机制方面的基础研究结果 卡氏肺孢子虫和其他可能有助于确定 在抗逆转录病毒治疗中，何时以及是否可以安全地停止预防性治疗 响应者。此外，探索微生物和免疫学方法，以确定 预防肺孢子虫作为辅助免疫的基础的风险- 以治疗和预防为基础。除研究其发病机制外，还需进一步研究其发病机制 HARRT时代丙型肝炎/艾滋病毒混合感染的临床意义 利用这些知识来开发改进的治疗方法。另一个目标是继续 阐明人类免疫缺陷病毒神经发病机制 感染，并利用这些机制开发新的治疗方法 中枢神经系统艾滋病毒感染的方式，包括艾滋病毒痴呆 和多灶性白质脑病。加州大学ACTU还将致力于开发 不和谐反应患者的治疗策略 目前的抗逆转录病毒疗法，并开发简单、有效的治疗方法 战略，包括使用新型药物，以加强抗逆转录病毒 依从性，从而改善临床结果。短期和长期 与各种因素相关的质量调整预期寿命的增量成本 使用效用评估的治疗策略也将被研究。最后， 加州大学ACTU建议评估一项密集的教育干预 这是由患者调整的，产生了改善的短期和长期病毒学 幼稚病人的压抑。

DESCRIPTION (adapted from the applicantion's abstract): Since its inception in 1987, the University of Cincinnati (UC) ACTU has made contributions to the overall mission of the ACTG in a number of key areas. The UC ACTU has provided both scientific and administrative leadership especially in opportunistic infections, and more recently, in antiretroviral studies, HIV- associated neurologic diseases, research nursing, and study design. In the current cycle, the UC ACTU proposes to continue to perform a broad range of clinical trials and substudies to assure maximum UC ACTU contribution to the objectives of the ACTG research agenda. These include to translate the findings of basic research conducted at UC on immunopathogenesis of Pneumocystis carinii and other opportunistic pathogens that may help determine when and if prophylaxis can be discontinued safely in antiretroviral therapy responders. Also, to explore microbial and immunologic measures which define risk for the protection against Pneumocystis as a basis for adjunctive immune- based therapy and prophylaxis. In addition to study the pathogenesis and clinical significance of hepatitis C/HIV co-infection in the HARRT era, and use this knowledge to develop improved treatments. Another Aim is to continue to elucidate the underlying mechanisms in the neuropathogenesis of HIV infection, and exploit these mechanisms in the development of new therapeutic modalities for central nervous system HIV infection, including HIV dementia and multifocal leukoencephalopathy. The UC ACTU will also work to develop treatment strategies for the management of patients with discordant responses to current antiretroviral therapy and to develop simplified, potent treatment strategies, including the use of novel agents, to enhance antiretroviral adherence and therefore improve clinical outcome. The short and longer-term incremental cost of quality-adjusted life expectancy associated with various treatment strategies using utility assessment will also be studied. Finally, the UC ACTU proposes to evaluate whether an intensive educational intervention that is paced by the patient yields improved short and long-term virologic suppression in naive patients.